Is Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Taysha Gene Therapies, Inc.
Taysha Gene Therapies Inc. (TSHA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 18,650,000 | $53,525,500 | +329% | 0.62% |
| 2. | RA Capital Management Peter Kolchinsky | 10,872,503 | $31,204,084 | -42% | 0.39% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,004,756 | $11,493,650 | 0.14% | |
| 4. | Tybourne Capital Management Eashwar Krishnan | 3,700,000 | $10,619,000 | 1.81% | |
| 5. | Acuta Capital Partners Manfred Yu | 3,333,333 | $9,566,666 | -8% | 6.21% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.25 | 1,333,333 | 1,333,333 | 2024-06-27 | Filing | ||
| $1.63 | 100,000 | Large Shareholder | 16,566,667 | 2023-11-17 | Filing | |
| $0.90 | 16,466,667 | Large Shareholder | 16,466,667 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | Director | 999,381 | 2023-08-16 | Filing | |
| $0.90 | 388,889 | Director | 884,290 | 2023-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.33 | 33,000 | Officer | 258,042 | 2023-08-24 | Filing | |
| $0.70 | 5,344 | 8,871,747 | 2023-07-13 | Filing | ||
| $0.71 | 80,528 | 8,877,091 | 2023-07-12 | Filing | ||
| $0.70 | 18,100 | Large Shareholder | 8,957,619 | 2023-06-23 | Filing | |
| $0.70 | 10,508 | Large Shareholder | 8,975,719 | 2023-06-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,439,124 | $39,717,250 | 0% | |
| 2. | 16,893,185 | $29,900,937 | 0.46% | |
| 3. | 10,412,872 | $18,430,783 | 1.26% | |
| 4. | 6,195,567 | $10,966,154 | 0% | |
| 5. | 2,912,861 | $5,155,764 | 0.57% |
News See All
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and understand the reasons behind...
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2024 Earnings Call Transcript
Operator: Greetings and welcome to the Taysha Gene Therapies First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript
Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $0.92, expectations were $-0.09.
5 Best Rising Penny Stocks To Buy
Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program.
Hedge Funds Say These 5 Penny Stocks are Poised to Explode
Below you can find the list of 5 penny stocks that are poised to explode according to hedge funds.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Taysha Gene Therapies Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Hedge Fund and Insider Trading News: Cathie Wood, Citadel LLC, Adage Capital Management, Hippo Holdings Inc (HIPO), Taysha Gene Therapies, Inc. (TSHA), and More
Cathie Wood extended her bet on Dutch payment processing company Adyen NV just after a growth slowdown sent the stock down by almost half to its lowest level in three years.
Hedge Fund and Insider Trading News: George Soros, Ray Dalio, Ken Griffin, Daniel Och, EDL Capital, Rokos Capital Management, Precigen Inc (PGEN), Sigilon Therapeutics, Inc. (SGTX), and More
George Soros has been branded as a bogeyman by the right wing for backing liberal causes around the globe.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2023 Earnings Call Transcript
Operator: Thank you for standing by. This is the conference operator. Welcome to the Taysha Gene Therapies First Quarter 2023 Earnings Conference Call.
Billionaire Hedge Funds
